Monday, March 09, 2015 3:45:59 PM
Food and Healthcare Likely to Carry 2015
Several collaborators will advance human therapeutics into
clinical trials this year. Overall, Intrexon figures that about 10
products developed with its assistance will be in testing. Ziopharm
alone will likely account for at least half of them and two other
companies, Fibrocell Science and Synthetic Biologics, will have
one each. Another therapy that was mentioned was developed as
part of the Sun Pharma joint venture in ophthalmology. Recently
acquired ActoGenix has two clinical-stage programs involving
genetically modified bacteria for oral mucositis and inflammatory
bowel disease, which will probably be partnered soon.
A pending acquisition will expand Intrexon’s presence in
the food sector… The Company has agreed to pay $41 million
for Okanagan Specialty Fruits, including $10 million in cash and
the remainder in XON stock. The deal, which should close by
June, will bring two approved, non-browning apple varieties into
the product line and add three similar genetically modified fruit
programs to the R&D pipeline. Note that we do not expect
revenues from Okanagan until 2017.
…while Trans Ova should drive revenues this year. This
subsidiary, which was acquired last August, will likely generate
close to $100 million in revenue from its dairy and cattle
embryo sales and in vitro fertilization services. Demand, which
is seasonally strongest in the June quarter, is growing at a rapid
pace.
Intrexon closed 2014 on a pleasant note. Fourth-quarter
revenues benefited from $15.1 million in sales and service
revenues from Trans Ova in its first full quarter with the
Company. The other major contributor was $13 million in
collaboration revenues. Operating expenses were generally in
line with expectations. The profit margin on product and service
revenues, which were generated largely by Trans Ova, amounted
to 29% during the seasonally weak December interim. R&D costs
increased 41%, to $59 million, while selling and administrative
expenses jumped 61%, to $64 million, due largely to acquisitions.
Overall, the operating loss increased modestly from year-toyear,
to $19 million. More than offsetting that was unrealized
appreciation in stocks of the Company’s collaborators, which
resulted in a $0.19-a-share profit in the quarter.
We are maintaining our BUY recommendation on Intrexon
shares and our $65 price target.
http://www.griffinsecurities.com/viewpdf.php?docid=959
I Love you cause you Hate me
Recent PGEN News
- Precigen to Participate in the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:00:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:25:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:19:00 PM
- Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates • PR Newswire (US) • 08/14/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 09:09:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:04:35 PM
- Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th • PR Newswire (US) • 08/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:19:45 PM
- Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock • PR Newswire (US) • 08/08/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 08:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Precigen Announces Proposed $30 Million Public Offering of Common Stock • PR Newswire (US) • 08/06/2024 08:04:00 PM
- Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:21:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:20:43 PM
- Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch • PR Newswire (US) • 07/23/2024 12:01:00 PM
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response • PR Newswire (US) • 06/03/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:03:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:45 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/28/2024 08:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:44:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM